Oral Cannabidiol Does Not Convert to Δ 8 -THC or Δ 9 -THC in Humans: A Pharmacokinetic Study in Healthy Subjects.

Autor:	Crippa JAS; Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.; National Institute of Science and Technology for Translational Medicine, Brazilian National Council for Scientific and Technological Development, Brasília, Brazil., Zuardi AW; Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.; National Institute of Science and Technology for Translational Medicine, Brazilian National Council for Scientific and Technological Development, Brasília, Brazil., Hallak JEC; Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.; National Institute of Science and Technology for Translational Medicine, Brazilian National Council for Scientific and Technological Development, Brasília, Brazil., Miyazawa B; Clinical Research Unit (UPC-HC-FMRP), Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil., Bernardo SA; Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.; National Institute of Science and Technology for Translational Medicine, Brazilian National Council for Scientific and Technological Development, Brasília, Brazil., Donaduzzi CM; Prati Donaduzzi & Cia Ltda, Toledo, Brazil., Guzzi S; Biocinese-Center for Biopharmaceutical Studies, Toledo, Brazil., Favreto WAJ; Biocinese-Center for Biopharmaceutical Studies, Toledo, Brazil., Campos A; Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil., Queiroz MEC; Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.; Departamento de Química da Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil., Guimarães FS; Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.; Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil., da Rosa Zimmermann PM; Prati Donaduzzi & Cia Ltda, Toledo, Brazil., Rechia LM; Prati Donaduzzi & Cia Ltda, Toledo, Brazil., Jose Tondo Filho V; Prati Donaduzzi & Cia Ltda, Toledo, Brazil., Brum Junior L; Prati Donaduzzi & Cia Ltda, Toledo, Brazil.
Jazyk:	angličtina
Zdroj:	Cannabis and cannabinoid research [Cannabis Cannabinoid Res] 2020 Feb 27; Vol. 5 (1), pp. 89-98. Date of Electronic Publication: 2020 Feb 27 (Print Publication: 2020).
DOI:	10.1089/can.2019.0024
Abstrakt:	Introduction: Recent studies have suggested that cannabidiol (CBD) could interconvert into Delta-8- and Delta-9- tetrahydrocannabinol. Materials and Methods: Thus, we tested the plasma samples of 120 healthy human subjects (60 male and 60 female), 60 in fasting and the other 60 under normal feeding conditions after acute administration of an oral solution containing CBD 300 mg. To do this, we developed a bioanalytical method to determine CBD and the presence of THC in plasma samples by Ultra-High Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry. Results: The results showed that THC was not detected in plasma after the administration of CBD, and those study participants did not present psychotomimetic effects. Conclusions: The findings presented here are consistent with previous evidence suggesting that the oral administration of CBD in a corn oil formulation is a safe route for the administration of the active substance without bioconversion to THC in humans. Competing Interests: J.A.S.C., A.W.Z., and J.E.C.H. are coinventors of the patent “Fluorinated CBD compounds, compositions and uses thereof. Pub. No.: WO/2014/108899. International Application No.: PCT/IL2014/050023,” Def. US number Reg. 62193296; July 29, 2015; INPI on August 19, 2015 (BR1120150164927; Mechoulam R, Zuardi A.W., Kapczinski F, Hallak J.E.C, Guimarâes F.S., Crippa J.A.S., Breuer A). The University of São Paulo has licensed the patent to Phytecs Pharm (USP Resolution No. 15.1.130002.1.1). The University of São Paulo has an agreement with PratiDonaduzzi Pharm to “develop a pharmaceutical product containing synthetic CBD and prove its safety and therapeutic efficacy in the treatment of epilepsy, schizophrenia, Parkinson's disease, and anxiety disorders.” J.A.S.C. is a member of the International Advisory Board of the Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE – National Health and Medical Research Council, NHMRC). (Copyright 2020, Mary Ann Liebert, Inc., publishers.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu